Marinus Pharmaceuticals, Inc. 61Y.F Stock
Marinus Pharmaceuticals, Inc. Price Chart
Marinus Pharmaceuticals, Inc. 61Y.F Financial and Trading Overview
| Marinus Pharmaceuticals, Inc. stock price | 1.23 EUR |
| Previous Close | 9.1 EUR |
| Open | 8.8 EUR |
| Bid | 8.8 EUR x N/A |
| Ask | 9.1 EUR x N/A |
| Day's Range | 8.8 - 8.8 EUR |
| 52 Week Range | 3.22 - 9.8 EUR |
| Volume | 685 EUR |
| Avg. Volume | 16 EUR |
| Market Cap | 536.31M EUR |
| Beta (5Y Monthly) | 1.152112 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.88 EUR |
61Y.F Valuation Measures
| Enterprise Value | 398.17M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.9139073 |
| PEG Ratio (5 yr expected) | -0.22 |
| Price/Sales (ttm) | 24.746874 |
| Price/Book (mrq) | 5.392157 |
| Enterprise Value/Revenue | 18.373 |
| Enterprise Value/EBITDA | -3.156 |
Trading Information
Marinus Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.152112 |
| 52-Week Change | 150.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.8 EUR |
| 52 Week Low | 3.22 EUR |
| 50-Day Moving Average | 7.17 EUR |
| 200-Day Moving Average | 5.89 EUR |
61Y.F Share Statistics
| Avg. Volume (3 month) | 16 EUR |
| Avg. Daily Volume (10-Days) | 68 EUR |
| Shares Outstanding | 50.55M |
| Float | 36.69M |
| Short Ratio | N/A |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 83.76% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -162.35% |
| Operating Margin (ttm) | -595.42% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -43.87% |
| Return on Equity (ttm) | -56.076% |
Income Statement
| Revenue (ttm) | 21.67M EUR |
| Revenue Per Share (ttm) | 0.51 EUR |
| Quarterly Revenue Growth (yoy) | -26.80% |
| Gross Profit (ttm) | -55943000 EUR |
| EBITDA | -126154000 EUR |
| Net Income Avi to Common (ttm) | -35185000 EUR |
| Diluted EPS (ttm) | -0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 199.2M EUR |
| Total Cash Per Share (mrq) | 3.94 EUR |
| Total Debt (mrq) | 105.54M EUR |
| Total Debt/Equity (mrq) | 124.04 EUR |
| Current Ratio (mrq) | 10.226 |
| Book Value Per Share (mrq) | 1.632 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -126709000 EUR |
| Levered Free Cash Flow (ttm) | -82011376 EUR |
Profile of Marinus Pharmaceuticals, Inc.
| Country | Germany |
| State | PA |
| City | Radnor |
| Address | 5 Radnor Corporate Center |
| ZIP | 19087 |
| Phone | 484 801 4670 |
| Website | https://marinuspharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 151 |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Q&A For Marinus Pharmaceuticals, Inc. Stock
What is a current 61Y.F stock price?
Marinus Pharmaceuticals, Inc. 61Y.F stock price today per share is 1.23 EUR.
How to purchase Marinus Pharmaceuticals, Inc. stock?
You can buy 61Y.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Marinus Pharmaceuticals, Inc.?
The stock symbol or ticker of Marinus Pharmaceuticals, Inc. is 61Y.F.
Which industry does the Marinus Pharmaceuticals, Inc. company belong to?
The Marinus Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Marinus Pharmaceuticals, Inc. have in circulation?
The max supply of Marinus Pharmaceuticals, Inc. shares is 56.37M.
What is Marinus Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Marinus Pharmaceuticals, Inc. PE Ratio is now.
What was Marinus Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Marinus Pharmaceuticals, Inc. EPS is -2.43 EUR over the trailing 12 months.
Which sector does the Marinus Pharmaceuticals, Inc. company belong to?
The Marinus Pharmaceuticals, Inc. sector is Healthcare.